154,045 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Corient Private Wealth LLC

Corient Private Wealth LLC acquired a new stake in Revvity, Inc. (NYSE:RVTY) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 154,045 shares of the company’s stock, valued at approximately $16,839,000. Corient Private Wealth LLC owned 0.12% of Revvity as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in RVTY. Balentine LLC purchased a new position in Revvity in the fourth quarter worth about $219,000. Coldstream Capital Management Inc. acquired a new position in Revvity during the fourth quarter worth $208,000. Motco acquired a new stake in Revvity during the fourth quarter worth about $287,000. UBS Group AG acquired a new stake in shares of Revvity during the fourth quarter worth about $11,034,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Revvity during the 4th quarter worth approximately $3,538,000. 86.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on RVTY. Raymond James raised their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. TD Cowen boosted their price target on shares of Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Robert W. Baird raised their price target on shares of Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a report on Tuesday, April 30th. Stifel Nicolaus raised their price target on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Finally, KeyCorp lifted their price target on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.17.

Revvity Stock Performance

RVTY traded up $1.38 during trading on Friday, hitting $113.27. 647,663 shares of the stock were exchanged, compared to its average volume of 850,169. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $131.96. The stock has a fifty day moving average price of $104.74 and a two-hundred day moving average price of $102.69. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $13.98 billion, a P/E ratio of 93.61, a PEG ratio of 2.91 and a beta of 1.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The firm had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. During the same period in the previous year, the company posted $1.01 earnings per share. Revvity’s revenue was down 3.7% compared to the same quarter last year. As a group, sell-side analysts predict that Revvity, Inc. will post 4.66 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Friday, July 19th. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.